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Epidemiology/Health Services Research
O R I G I N A L

A R T I C L E

Fasting Insulin Level Is Positively
Associated With Incidence of
Hypertension Among American
Young Adults
A 20-year follow-up study
PENGCHENG XUN, MD,
KIANG LIU, PHD3
WENHONG CAO, MD1

PHD

1,2

STEPHEN SIDNEY, MD, MPH4
O. DALE WILLIAMS, PHD5
KA HE, MD, SCD1,2

OBJECTIVEdAlthough hyperinsulinemia, a surrogate of insulin resistance, may play a role in
the pathogenesis of hypertension (HTN), the longitudinal association between fasting insulin
level and HTN development is still controversial. We examined the relation between fasting
insulin and incidence of HTN in a large prospective cohort.
RESEARCH DESIGN AND METHODSdA prospective cohort of 3,413 Americans, aged
18–30 years, without HTN in 1985 (baseline) were enrolled. Six follow-ups were conducted in
1987, 1990, 1992, 1995, 2000, and 2005. Fasting insulin and glucose levels were assessed by a
radioimmunoassay and hexokinase method, respectively. Cox proportional hazards models
were used to calculate hazard ratios (HRs) and 95% CIs of incident HTN (deﬁned as the initiation
of antihypertensive medication, systolic blood pressure $140 mmHg, or diastolic blood pressure
$90 mmHg).
RESULTSdDuring the 20-year follow-up, 796 incident cases were identiﬁed. After adjustment for potential confounders, participants in the highest quartile of insulin levels had a signiﬁcantly higher incidence of HTN (HR 1.85 [95% CI 1.42–2.40]; Ptrend , 0.001) compared
with those in the lowest quartile. The positive association persisted in each sex/ethnicity/weight
status subgroup. A similar dose-response relation was observed when insulin-to-glucose ratio or
homeostatic model assessment of insulin resistance was used as exposure.
CONCLUSIONSdFasting serum insulin levels or hyperinsulinemia in young adulthood was
positively associated with incidence of HTN later in life for both men and women, African
Americans and Caucasians, and those with normal weight and overweight. Our ﬁndings suggested that fasting insulin ascertainment may help clinicians identify those at high risk of HTN.

Some epidemiological studies, including both cross-sectional and longitudinal studies, have indicated that insulin
levels are associated with blood pressure
(BP) as well as incidence of HTN (5–7).
However, inconsistent ﬁndings (8,9),
especially in a speciﬁc sex or ethnic subgroup (10,11), made this topic a controversy. In addition, among the limited
prospective studies on the association of
insulin level with incidence of HTN
(5,6,9,12–14), most have been conducted in only one sex or one ethnic group
(9,12–14). Few studies have examined
the association in both men and women,
and African Americans (AAs) and Caucasians (5,6). Therefore, we prospectively
examined fasting insulin level in relation
to incidence of HTN in a large biracial cohort of American men and women over
20 years of follow-up using data from the
Coronary Artery Risk Development in
Young Adults (CARDIA) study.
RESEARCH DESIGN AND
METHODS

Diabetes Care 35:1532–1537, 2012

H

ypertension (HTN), a leading cause
of cardiovascular morbidity and
mortality, has become an important
public health burden worldwide (1). It
has been well established that HTN tends
to coexist with diabetes (2,3), either preceding or being the complication of

diabetes. In addition, the risk factors for
HTN and diabetes are prone to cluster together, and it has been hypothesized that
hyperinsulinemia, a surrogate measure of
insulin resistance, might provide the pathophysiological mechanism underlying
these observations (4).
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Study design
The CARDIA study is an ongoing, prospective, multicenter, observational study
of the natural history of the development
of cardiovascular disease risk from young
adulthood to midlife. In 1985, 5,115
young adults between the ages of 18 and
30 years were randomly selected from
four U.S. cities: Birmingham, Alabama;
Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California. The sampling scheme was designed to achieve a
balance at each site by age (18–24 and
25–30 years), sex, ethnicity (AA and Caucasian), and education (high school degree or less and more than high school).
To date, six follow-ups have been conducted at examination years 2, 5, 7, 10,
15, and 20. Follow-up rates averaged
.90%, and ;70% of the participants in
the original cohort returned at year 20.
care.diabetesjournals.org
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More details of the study design and recruitment protocol have been previously
reported (15). The institutional review
committee approval and informed consent was obtained for each examination.
Among those who had serum insulin
measured at baseline (n = 3791), we excluded participants who had not fasted
for at least 8 h (n = 80) or were pregnant
at any examination (n = 200) or were diagnosed as HTN at baseline (n = 98) in a
sequential manner. After all these exclusions, 3,413 participants remained in the
sample.
Ascertainment of insulin and glucose
Fasting blood samples were collected
according to standardized CARDIA procedures and processed at central laboratories (15). Fasting serum insulin was
measured originally by a nonspeciﬁc insulin assay at baseline and in later examinations by a new radioimmunoassay
(Linco Research Inc., St. Charles, MO).
To assure comparability of insulin across
visits, sera stored from baseline was remeasured by the new assay 8 years later
(16). The Pearson correlation of log insulin values for baseline by the original (17)
and the new method (18) was 0.81. Fasting glucose was detected by hexokinase
method on a Cobas Mira Plus chemistry
analyzer at each examination (16). On the
basis of re-assays of glucose in 2006 and
2007 in ;200 samples per examination
drawn at years 7, 10, 15, and 20, and of
insulin in 100 samples stored since year
15, glucose and insulin were recalibrated
to harmonize them with the previous
measurements. Recalibrated glucose values were 6.98 + 0.94 3 year 7 glucose
concentration, 7.15 + 0.96 3 year 10 glucose concentration, 6.99 + 1.01 3 year 15
glucose concentration, and 4.06 + 0.97 3
year 20 glucose concentration. Recalibrated insulin was 20.36 + 0.93 3 year 20
insulin concentration (19). Homeostatic
model assessment of insulin resistance
(HOMA-IR) was calculated as glucose
(mmol/L) 3 insulin (mU/L)/22.5 (20).
Ascertainment of HTN
BP was measured at the ﬁrst six examinations using the Hawksley random-zero
sphygmomanometer (W.A. Baum Co.,
Copiague, NY) and at the seventh (examination year 20) using the OmROn
HEM907XL by trained and certiﬁed technicians (21). Three BP measurements
were taken from the right arm of each participant at 1-min intervals after a 5-min
seated rest. Systolic BP (SBP) and diastolic
care.diabetesjournals.org

BP (DBP) were recorded as phase I and
phase V Korotkoff sounds through examination year 15. Based on a study of ;900
participants, we estimated SBP (random
zero) = 3.74 + 0.96 3 observed OmROn
SBP and estimated DBP = 1.30 + 0.97 3
observed OmROn DBP at examination
year 20 (22). The second and third of
the measurements were averaged for all
analyses.
HTN was deﬁned as SBP $140
mmHg and/or DBP $90 mmHg and/or
taking antihypertensive medication at
each examination. HTN incidence was
deﬁned as the percentage of nonhypertensive participants at baseline who developed HTN at the 20-year follow-up.
Measurement of covariates
Demographic variables, including age, sex,
ethnicity, and education level, were collected
using a self-administered questionnaire
and veriﬁed during clinic examinations.
Education level was classiﬁed as ,12, 12,
13–15, and $16 years. Anthropometric
measures were collected with participants
wearing light clothing and no shoes. Body
weight was measured to nearest 0.5 lb
using a calibrated scale. Height was measured to the nearest 0.5 cm with a vertical
ruler. BMI was calculated as weight in
kilograms divided by height in meters
squared.
Smoking status was determined by an
interviewer-administered questionnaire
and participants were categorized into
three groups: nonsmokers, former smokers, and current smokers. Alcohol consumption was measured by the question,
“Do you drink any alcoholic beverages in
the past year?” If the answer was yes, it
was followed by three questions on how
many servings of wine, beer, and liquor.
Total ethanol consumption in milliliters
per day was estimated from the answers
about individual alcoholic beverages using the formula ([beer servings/week 3
16.7] + [wine servings/week 3 17.02] +
[liquor servings/week 3 19.09])/7, and
was categorized into six groups: 0 (never
drink), 0.1–4.9, 5.0–9.9, 10–14.9, 15.0–
29.9, and $30 mL/day. Physical activity
was assessed using the CARDIA Physical Activity History Questionnaire, an
interviewer-administered self-report of frequency of participation in 13 categories
of recreational sports, exercise, leisure,
and occupational activities over the previous 12 months. Physical activity score
was calculated in exercise units (EU)
based on the frequency and duration of
activity over the previous year. A score of

100 EU is roughly equivalent to engaging
in vigorous activity 2–3 h/week for 6
months of the year.
Dietary intakes of sodium, potassium,
and magnesium were assessed by the
CARDIA Diet History Questionnaire, an
interviewer-administrated quantitative
food frequency questionnaire, which has
been evaluated and discussed elsewhere
(23). Diet assessment was conducted
three times: at baseline and examination
years 7 and 20.
Statistical analysis
Participants were divided into quartiles
according to insulin levels (mU/mL).
Baseline characteristics of participants
were expressed as mean (SD), median
(interquartile range), or proportion and
were compared across quartiles by using
ANOVA, Kruskal-Wallis test, or x2 test
as appropriate. We used Cox proportional
hazards models to evaluate associations of
serum insulin levels, insulin-to-glucose
ratio (IGR), and HOMA-IR with incidence
of HTN. Follow-up time was calculated as
the difference between the baseline examination and the year in which HTN was
ﬁrst identiﬁed, year 20, or the year a participant was censored. We used nonparametric splines to examine whether there
was a nonlinear relation of exposure of interest with incidence of HTN. We used
generalized estimating equations (GEEs)
with identity linkage under exchangeable
correlation structure assumption to examine exposures of interest in relation
to continuous SBP and DBP.
To reduce measurement error caused
by within-person variation and to best
represent long-term insulin level (IGR or
HOMA-IR) prior to HTN, we used cumulative average values of the exposures of
interest (24). For example, we related the
insulin levels (IGR or HOMA-IR) measured at baseline to new HTN cases identiﬁed at examination years 2, 5, and 7, and
the average of insulin levels (IGR or
HOMA-IR) detected at baseline and years
7, 10, and 15 to new cases identiﬁed at
year 20. To explore whether the duration
of follow-up would affect the associations, we also used the baseline exposure
model and the most recent exposure
model in the sensitivity analyses (24).
We categorized exposures of interest
into quartiles based on their distributions.
The initial analysis (model 1) was adjusted
for age, sex, ethnicity, and study center. In
model 2, we further adjusted for BMI, education, smoking status, alcohol consumption, physical activity, baseline systolic BP,
DIABETES CARE, VOLUME 35, JULY 2012
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and family history of HTN, and in model 3,
we additionally adjusted for dietary intakes
of sodium, potassium, and magnesium.
Glucose was also adjusted in the ﬁnal
model when insulin was used as exposure.
Ordinal variables using the median value
in each quartile were created for trend
tests. As antihypertensive medication information was used to deﬁne incident
cases of HTN, we did not include it in
Cox models and only included it for GEE
analysis.
In addition, we investigated whether
sex, ethnicity, and overweight/obese status modiﬁed the relations between insulin
level and incidence of HTN. These analyses were performed by creating interaction terms of exposure of interest with
these potential modiﬁers. The P values for
interaction were calculated from likelihood ratio test by comparing models
with and without the interaction terms.
All analyses were performed using
SAS 9.2 (SAS Institute Inc., Cary, NC).
P #0.05 was considered statistically
signiﬁcant.
RESULTSdTable 1 shows the baseline
characteristics of 3,413 participants according to quartiles of serum insulin level.
The cumulative median levels of insulin
were 7.8, 9.8, 12.3, and 18.0 mU/mL
across quartiles. At baseline, the mean

age of study population was 25.0 6 3.6
years and the mean BMI was 24.4 6 4.8
kg/m2. Compared with participants in the
lowest quartile of insulin level, those in
the highest quartile were slightly younger,
more likely to be females, AAs, and noncurrent smokers, and had relatively lower
education level and lower alcohol consumption. They were less likely to be active and lean.
A total of 796 incident cases of HTN
were identiﬁed (incident rate = 13.7/
1,000 person-years) during 57,920 personyears of follow-up. As illustrated in Table 2,
insulin levels were positively and signiﬁcantly associated with incidence of HTN.
Participants in the highest quartile of insulin level had a signiﬁcantly higher incidence of HTN (hazard ratio [HR] 1.85
[95% CI 1.42–2.40]; P trend , 0.001)
compared with those in the lowest quartile, after adjustment for potential confounders. Nonparametric spline analysis
did not suggest any nonlinear association
such as a “threshold” relation. Every unit
increase of fasting insulin was associated
with a 1.03-fold higher risk of incident
HTN (95% CI 1.02–1.04). A similar signiﬁcant dose-response relation was observed for IGR (Q4 vs. Q1: HR 1.78 [95%
CI 1.35–2.37]; P trend , 0.001) and
HOMA-IR (Q4 vs. Q1: 1.27 [1.00–1.63];
Ptrend , 0.001). When we further stratiﬁed

data by sex or ethnicity, the observed
positive associations remained consistent
in each subgroup and none of the tests for
interactions was statistically signiﬁcant.
Moreover, to test whether the observed
positive association was solely driven by
overweight/obese status, we did a fully
stratiﬁed analysis by creating different
quartiles within the stratum of normal
weight and overweight/obese, and the similar positive associations were documented
within each subgroup.
Using GEE, we found that insulin
level was positively associated with both
SBP and DBP. The multivariable-adjusted
b coefﬁcients comparing the highest to
the lowest quartiles of insulin levels
were 3.64 mmHg (95% CI 2.82–4.46
mmHg; Ptrend , 0.001) and 2.34 mmHg
(1.65–3.03 mmHg; Ptrend , 0.001) for
SBP and DBP, respectively. A similar signiﬁcant dose-response relation was also
observed for the association of IGR or
HOMA-IR with SBP and DBP (data not
shown). When we examined the associations among normotensive individuals,
the positive associations were essentially
the same.
Sensitivity analyses were conducted
to test the robustness of our main ﬁndings. First, we used the baseline exposure
model and the most recent exposure
model to explore the possible effect of

Table 1dBaseline characteristics by quartile of fasting insulin level (CARDIA study, 1985–2005*)
Quartile of insulin level
Baseline characteristic
Insulin level, mU/mL
Glucose level, mg/dL
IGR, (mU/mL)/(mg/dL)
HOMA-IR
SBP, mmHg
DBP, mmHg
Age, years
Female, %
AA, %
Education, years
Current smokers, %
Alcohol consumption, mL/day
Physical activity, EU
BMI, kg/m2
Family history of HTN, %
Dietary intake,
mg/1,000 kcal/day
Sodium
Potassium
Magnesium

1 (n = 795)

2 (n = 849)

3 (n = 921)

4 (n = 848)

Total
(n = 3,413)

P value

7.8 (7.0–8.3)
84.2 (80.8–88.6)
0.09 (0.08–0.10)
1.6 (1.4–1.8)
108.2 (10.5)
67.1 (9.2)
25.5 (3.3)
52.8
33.1
14.2 (2.3)
31.3
7.2 (0.0–19.2)
433 (245–642)
21.9 (2.7)
44.0

9.8 (9.3–10.3)
86.0 (82.5–90.0)
0.11 (0.11–0.12)
2.1 (1.9–2.2)
109.7 (10.0)
68.2 (8.5)
25.1 (3.6)
50.5
40.3
14.0 (2.3)
29.5
5.1 (0.0–16.9)
404 (236–638)
23.0 (3.1)
47.1

12.3 (11.5–13.0)
87.7 (83.4–91.8)
0.14 (0.13–0.15)
2.6 (2.5–2.9)
110.3 (9.7)
68.5 (9.0)
24.6 (3.7)
50.0
50.6
13.9 (2.2)
26.4
4.8 (0.0–15.0)
366 (208–568)
24.4 (4.1)
50.0

18.0 (16.0–22.7)
90.2 (85.4–95.2)
0.20 (0.18–0.24)
4.0 (3.5–5.3)
112.2 (10.1)
69.3 (9.4)
24.9 (3.7)
57.3
63.2
13.6 (2.2)
27.4
2.4 (0.0–10.2)
296 (155–496)
28.1 (6.0)
55.1

11.0 (9.0–14.3)
87.0 (82.8–91.6)
0.13 (0.10–0.16)
2.4 (1.9–3.1)
110.1 (10.1)
68.3 (9.0)
25.0 (3.6)
52.6
47.1
13.9 (2.3)
28.6
4.8 (0.0–15.0)
372 (208–589)
24.4 (4.8)
49.1

d
d
d
d
,0.001
,0.001
,0.001
0.009
,0.001
,0.001
0.016
,0.001
,0.001
,0.001
,0.001

1,503.9 (311.4)
1,423.4 (410.5)
157.1 (58.5)

1,500.0 (302.1)
1,395.1 (409.9)
149.2 (55.3)

1,497.7 (275.3)
1,321.5 (359.7)
138.8 (45.3)

1,490.4 (299.4)
1,269.4 (337.4)
130.0 (41.1)

1,497.9 (296.6)
1,350.6 (384.3)
143.5 (51.3)

0.821
,0.001
,0.001

*Data are mean (SD), median (interquartile range), or proportion as appropriate. P values for difference across all quartiles of insulin level were calculated with
ANOVA, Kruskal-Wallis test, or x2 test as appropriate.
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Table 2dMultivariable-adjusted HRs (95% CIs) of incidence of HTN by serum levels (quartiles) of insulin, IGR, or HOMA-IR
(CARDIA study, 1985–2005*)
Quartile of exposure of interest
1 (lowest)

2

3

4 (highest)

Ptrend

,9.0
113
13,836
8.2
1.00
1.00
1.00
,0.103
124
14,930
8.3
1.00
1.00
1.00
,1.88
129
14,408
9.0
1.00
1.00
1.00

9.0–10.9
144
14,714
9.8
1.11 (0.87–1.42)
1.03 (0.80–1.32)
1.13 (0.87–1.45)
0.103–0.125
143
14,971
9.6
1.15 (0.90–1.46)
1.19 (0.93–1.52)
1.18 (0.92–1.51)
1.88–2.37
148
14,920
9.9
1.01 (0.80–1.29)
0.98 (0.77–1.25)
0.99 (0.77–1.26)

11.0–14.2
209
15,523
13.5
1.44 (1.14–1.81)
1.28 (1.00–1.64)
1.48 (1.15–1.90)
0.126–0.160
202
14,567
13.9
1.47 (1.17–1.85)
1.40 (1.10–1.78)
1.39 (1.09–1.77)
2.38–3.13
197
14,536
13.6
1.28 (1.02–1.60)
1.07 (0.84–1.35)
1.06 (0.84–1.35)

$14.3
330
13,847
23.8
2.33 (1.87–2.90)
1.54 (1.19–1.98)
1.85 (1.42–2.40)
$0.161
326
13,627
23.9
2.46 (1.99–3.05)
1.80 (1.40–2.31)
1.78 (1.39–2.29)
$3.14
321
14,051
22.8
1.99 (1.62–2.45)
1.27 (1.00–1.62)
1.27 (1.00–1.63)

d
d
d
d
,0.001
,0.001
,0.001
d
d
d
d
,0.001
,0.001
,0.001
d
d
d
d
,0.001
0.013
0.013

Insulin level, mU/mL
HTN cases
Person-years
Incidence (per 1,000 person-years)
Model 1
Model 2
Model 3
IGR, (mU/mL)/(mg/dL)
HTN cases
Person-years
Incidence (per 1,000 person-years)
Model 1
Model 2
Model 3
HOMA-IR
HTN cases
Person-years
Incidence (per 1,000 person-years)
Model 1
Model 2
Model 3

*Cox proportional hazards models were used to calculate HRs and 95% CIs. Continuous variables using medians in each quartile were created for the trend tests.
Model 1, adjusted for age, sex, ethnicity (AA or Caucasian), and study center. Model 2, same as model 1 but with additional adjustment for BMI (quartiles), physical
activity (quartiles), education (,12, 12, 13–15, 16, or .16 years), smoking status (non, former, or current smokers), alcohol consumption (0, 0.1–4.9, 5.0–9.9,
10.0–14.9, 15.0–29.9, or $30 mL/day), baseline SBP (continuous), and family history of HTN (yes or no). Model 3, same as model 2 but with additional adjustment
for dietary intakes (quartiles) of sodium, potassium, and magnesium. Glucose (quartiles) was only additionally adjusted when using insulin levels as exposure.

follow-up time on the observed associations (Table 3). No material differences
were found between long-term and
short-term exposures. Second, when we
further excluded 120 participants with
baseline SBP/DBP $130/85 mmHg, the
multivariable adjusted HR of participants
in the highest quartile was 1.83 (95% CI
1.38–2.42; Ptrend , 0.001), as compared
with those in the lowest quartile. Third,
we additionally excluded 249 participants who were diagnosed as incident
HTN only by antihypertensive medication; the results were similar (1.81
[1.30–2.52]; Ptrend , 0.001). In addition,
as insulin levels were unavailable at examination years 2 and 5, we re-examined
three exposures of interest in relation to
incidence of HTN using examination
year 7 as baseline. After adjustment for
the same covariates listed for model 3 in
Table 2, the results remained (data not
shown).
CONCLUSIONSdIn this unique 20year follow-up longitudinal study, we found
that fasting insulin level and its two derived indices (i.e., IGR and HOMA-IR)
were positively associated with incidence
care.diabetesjournals.org

of HTN as well as SBP and DBP in a doseresponse manner among young AAs and
Caucasians. Sex, ethnicity, and BMI status
did not signiﬁcantly modify the observed
associations.
The ﬁndings of our study are generally in accordance with the results of previous studies. Serum insulin was found
to be positively associated with incident
HTN in 3,513 middle- or elder-aged
individuals with a 5-year follow-up in
Multi-Ethnic Study of Atherosclerosis
(MESA) (6). Likewise, the positive association was found in 377 middle-aged participants with a 7-year follow-up from the
Baltimore, MD, Clinical Center of Trials of
HTN Prevention, Phase 1 (5). There were
still a number of other supportive studies
(9,12–14,25), although they were either
relatively short-term (9,13), using a retrospective design (12,14,25), or only focusing on one sex or ethnic group (9,12,14).
However, unlike in our study, the
positive association was not consistently
observed in some ethnicity/sex subgroups
in other studies. For example, positive
association of fasting insulin level with
SBP and DBP was documented in nonHispanic whites but not in Mexican

Americans in 8-year follow-up San Antonio
Heart Study (26). The racial difference
was also found in another study, in which
positive association was only found in
Caucasians but not in AAs and Pima
Indians (11). In National Health and
Nutrition Examination Survey (NHNES)
1999–2002, higher fasting insulin .12.2
mU/mL or HOMA-IR $2.6 was found to
be positively associated with pre-HTN in
men but not in women. In addition, sex
difference in insulin-HTN relation was
reported in 527 AAs aged 18–55 (10).
Moreover, some studies reported ﬁndings contrary to our observations. Acute
physiological increases in plasma insulin
did not elevate arterial pressure of 13 borderline hypertensive young adults (27).
In a double-blind crossover study, administration of insulin exerted a small
BP-lowering effect on 23 nondiabetic,
untreated patients with essential HTN
(28). Of note, both of these small-sized
studies investigated the short-term effect
of insulin on pre-HTN or HTN. By contrast, our present study is elucidating a
long-term association of insulin with
incident HTN among normotensive
participants.
DIABETES CARE, VOLUME 35, JULY 2012
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Table 3dA sensitivity analysis of multivariable-adjusted HRs (95% CIs) of incidence of HTN by quartiles of exposure of interest
(CARDIA study, 1985–2005*)
Quartile of exposure of interest

Baseline model
Insulin level, mU/mL
IGR, (mU/mL)/(mg/dL)
HOMA-IR
Most recent model
Insulin level, mU/mL
IGR, (mU/mL)/(mg/dL)
HOMA-IR

1 (lowest)

2

3

4 (highest)

P for trend

1.00
1.00
1.00

1.13 (0.91–1.41)
1.09 (0.86–1.54)
1.02 (0.82–1.28)

1.03 (0.80–1.32)
1.22 (0.98–1.54)
0.98 (0.78–1.23)

1.50 (1.20–1.87)
1.50 (1.19–1.90)
1.27 (1.02–1.58)

,0.001
,0.001
0.014

1.00
1.00
1.00

1.41 (1.08–1.84)
1.60 (1.21–2.11)
1.25 (0.96–1.64)

1.74 (1.32–2.30)
1.79 (1.36–2.35)
1.32 (1.01–1.72)

1.99 (1.50–2.64)
2.21 (1.67–2.92)
1.43 (1.09–1.88)

,0.001
,0.001
0.027

*Cox proportional hazards models were used to calculated HRs and 95% CIs. Continuous variables using medians in each quartile were created for the trend tests. The
adjusted covariates in the models were the same as those listed for model 3 in Table 2.

The ﬁndings from this study are biologically plausible. Insulin can increase
BP through all primary components that
determine BP, including cardiac output,
blood volume, and vascular ﬂexibility.
Insulin, a well-established inotropic agent
(29), can increase cardiac output. Insulin
can increase blood volume through stimulating secretion of vasopressin (an antidiuretic) (30) and renal sodium retention
(31). Insulin can increase vascular tone
through several mechanisms. First, it
can increase basal level of calcium in cytosol of vascular smooth muscle cells by
promoting the voltage-dependent Ca2+
inﬂux and inhibiting Na+/Ca2+ exchanger–
dependent Ca2+ extrusion, leading to increased vascular tone (32). Second, it can
stimulate the rennin-angiotensin system
(33). Third, it can stimulate the secretion
of endohelin-1 (34), a vascular constrictor. Therefore, insulin can increase BP
in many different ways. However, this
primary role of insulin in increasing BP
has not been fully appreciated due to the
popular perception that insulin is not
functional in the presence of insulin resistance, which is tightly linked to increased BP. Nevertheless, studies have
shown that insulin is functional at an increased basal level in the presence of insulin resistance and hyperinsulinemia (35).
Some researchers argued that the relation between insulin resistance and
HTN is probably not unidirectional
(36). However, the likelihood of high BP
causing elevated insulin levels is presumably very low, because changes in insulin
level usually precede the presence of obvious HTN in metabolic diseases (37). In
addition, a large body of evidence lends
credence to the increase of BP by insulin
(38,39), but no existing evidence,
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DIABETES CARE, VOLUME 35, JULY 2012

especially in mechanism, supports that
HTN might cause hyperinsulinemia.
There are several strengths that need
to be emphasized in this study. First,
although randomized, placebo-controlled
trials are the best approach to establish
causal inference, it may not be feasible to
conduct one on this topic, which makes
the results from a well-designed prospective cohort study with relatively large
sample size and long-term follow-up
highly valuable. Second, the BP of our
participants was measured by trained
personnel using standardized procedures
rather than self-reported, which may substantially reduce possible measurement
error in BP. Importantly, the participants
were young (at their ages of 18–30 years)
at baseline, which enables us to investigate the evolution of cardiovascular disease risk by following the course of BP
and the appearance of incident HTN in
young adulthood.
Our study also has several limitations.
First, insulin levels were not obtained at
examination years 2 and 5. However, our
results were unlikely to be biased substantially because we used accumulative
models to approach the long-term exposure. Of note, when we used examination
year 7 as baseline, the results were consistent. Another concern is that the assays
of baseline insulin were measured again 7
years later. However, this would not
materially alter our results. In one study,
no signiﬁcant change was detected in
repeated assays of 34 samples stored at
2208C over an 8-year period (40). Also,
the correlation between log insulin values
from these two methods was high (r =
0.81) and would have little effect on the
association between insulin levels and
incident HTN. In fact, the re-assay of

baseline insulin levels with the same
method used in later examinations may
reduce the measurement error and
strengthen our study. Third, the CARDIA
cohort represents young AAs and Caucasians recruited from four metropolitan
areas in the U.S. and was not nationally
representative, which may limit the generalizability of our ﬁndings.
In conclusion, this prospective study
suggests that fasting serum insulin levels
are positively and longitudinally associated
with BP and incidence of HTN in apparently healthy American young adults, including both men and women, and AAs
and Caucasians. The ﬁndings from the
current study may help clinicians identify
those who are at high risk of HTN, and
support that lifestyle modiﬁcation to decrease insulin concentrations may be of
great importance for HTN prevention.
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